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Background: The use of dried blood spot (DBS) sampling is an alternative to traditional venous blood collection,
and particularly useful for people living in rural and remote areas, and for those who are infirm, house-bound or
time-poor. The objective of this study was to assess whether the measurement of glycated haemoglobin A1c
(HbA1c) in DBS samples provided comparative and acceptably precise results.
Methods: Venous and capillary blood samples were collected from 115 adult participants. After proper instruction,
each participant punctured his/her own finger and collected capillary blood samples on pieces of a proprietary
cellulose filter paper. Each filter paper was subsequently placed inside a breathable envelope, stored at room
temperature, and processed on the same day (D0), four (D4), seven (D7) and fourteen (D14) days after collection.
HbA1c was measured in duplicates/triplicates in whole venous blood (WB), capillary blood (capDBS) and venous
blood placed on the matrix paper (venDBS), by turbidimetric inhibition immunoassay. Intra-assay coefficients of
variation (CV) were calculated. DBS values were compared to WB results using linear regression, Bland-Altman
plots and cross-validation models.
Results: Eleven and 56 patients had type 1 and type 2 diabetes mellitus, respectively. Mean HbA1c levels were 6.22 ±
1.11 % for WB samples (n = 115). The median intra-assay CV was lower than 3 % for WB and capDBS on all days.
Results from capDBS and venDBS showed high correlation and agreement to WB results, with narrow 95 % limits
of agreement (except for results from D14 samples), as observed in Bland-Altman plots. When capDBS values
were applied to equations derived from regression analyses, results approached those of WB values. A cross-validation
model showed that capDBS results on D0, D4 and D7 were close to the WB results, with prediction intervals that were
narrow enough to be clinically acceptable.
Conclusions: The measurement of HbA1c from DBS samples provided results that were comparable to results from
WB samples, if measured up to seven days after collection. Intra-assay coefficients of variation were low, results
were in agreement with the gold-standard, and prediction intervals were clinically acceptable. The measurement
of HbA1c through DBS sampling may be considered in situations where traditional venipuncture is not available.
Trial registration: Australian New Zealand Clinical Trials Registry ID ACTRN12613000769785.
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Glycated haemoglobin (HbA1c) is a biomarker that is
fundamental for the diagnosis of diabetes and for monitor-
ing glycaemic control [1]. Traditionally, its measurement
depends on venipuncture, and on processing, transporta-
tion and storage of whole blood (WB) samples, which can
be logistically challenging [2]. These challenges can some-
times compromise proper diagnosis and treatment of
patients with diabetes mellitus.
An alternative blood sampling method, based on the
use of a dry matrix, was first described in the literature
over a century ago [3], and subsequently applied in the
clinics to detect metabolic defects through the collection
of heel capillary blood samples from newborns [4]. This
method is centred on collecting blood samples obtained
from finger or heel puncturing on a matrix paper, which
is subsequently dried. These dried blood spots (DBS)
can then be used for the measurement of diverse sub-
stances, including HbA1c, and requires minimal training
of staff, is cheaper and safer, eliminates the need for
special transportation logistics, and is more acceptable
to study participants [5–7].
DBS sampling has been routinely and successfully used
for the screening of congenital metabolic and endocrine
diseases, such as phenylketonuria and hypothyroidism [8].
More recently, studies have shown that measurements of
inflammatory markers, cytokines, serum antibodies, hu-
man immunodeficiency virus (HIV) loads and blood
hormone levels provide results that are comparable to
those obtained from standard venous samples [5, 9–11].
Dried blood spot sampling is also useful for the meas-
urement of HbA1c in individuals with and without dia-
betes. A recent meta-analysis of seventeen heterogeneous
studies demonstrated that HbA1c results from DBS were
correlated to those obtained through venipuncture [12].
However, there is still a need for standardisation of sample
collection, transportation, storage and analysis. In this
study, we evaluated HbA1c levels collected on a novel
matrix paper and measured through immunoturbidity, up
to 14 days after DBS collection. Subsequently, to demon-
strate whether DBS provide results comparable to WB
samples, DBS results were compared against those ob-
tained from standard methods.
Methods
This study was approved by the Australian National
University Human Research Ethics Committee, and all
participants provided informed consent. We recruited
participants from the general population living within
the Australian Capital Territory region, Australia. In-
clusion criteria allowed all adults over 18 years-old
from all genders and ethnicities that had no restrictions
to having their blood drawn (i.e. due to religious mat-
ters, or blood donation in the previous 4 weeks, ordifficulty in providing venous blood samples). Partici-
pants were advised not to consume food, alcohol or
caffeine for 12 h prior to the collection.
Venous blood was collected from an arm vein following
standard sterile techniques, into EDTA-coated plastic
tubes, providing WB samples. For the collection of capil-
lary DBS (capDBS) samples, we used a 2 x 3 inch dry
matrix cellulose paper with nine 10-mm outer diameter
circles printed on the surface (ITL Healthcare Pty Ltd).
Each printed circle has the capacity to hold 30 to 40
microlitres of blood. Participants were instructed to collect
their capillary blood through finger pricking and placing
one drop of blood onto each of the pre-defined circles of
the dry matrix paper, at room temperature (23 ° C). The
matrix paper was then placed into a breathable envelope
(ITL Healthcare Pty Ltd) for transportation to the testing
laboratory, and blood spots were allowed to dry at room
temperature for >2 h before transportation. Forty-
microlitre drops of venous blood were also pipetted from
collection tubes with no anticoagulant and immediately
placed on another dry matrix card, providing venous DBS
(venDBS) samples.
All blood samples were transported to the pathology
laboratory for analysis. HbA1c levels were determined
by a direct turbidimetric inhibition immunoassay that
determines HbA1c as a percentage of total haemoglobin
(%HbA1c) (Thermo Fisher Scientific). Assays were per-
formed on an Indiko Plus (Thermo Fisher Scientific)
automated biochemistry analyser, and results were re-
ported as %HbA1c NGSP values.
Processing of DBS samples (capDBS and venDBS): For
each participant sample, two punches were taken from
one DBS near the outer edge of the spot. Each punch
had 3.2 mm in diameter and contains approximately
1.4 μL of serum. Punches were placed in haemolysing
reagent (Thermo Fisher Scientific), in duplicate or tripli-
cate, and incubated at room temperature with shaking.
For each duplicate, one milliliter of haemolysate was
processed in the Indiko analyser as per the standard
protocol for whole blood. capDBS and venDBS samples
were processed and analysed on the same day (D0), and
on D4, D7 and D14, in duplicates or triplicates for the
calculation of intra-assay coefficients of variation (CV).
Processing of WB samples: WB samples were prepared
and processed as per standard protocol (Thermo Fisher
Scientific). WB samples were processed and analysed on
the same day (D0), in duplicates.
Results were presented as mean ± SD or median and
range. Linear regression models for predicting WB from
DBS were fit and goodness-of-fit measures [mean stand-
ard error (MSE) and R-squared] were estimated using
cross-validation (R program developed for the cross-
validation available upon request). From these models,
we predicted WB from DBS values of 4 %, 7 %, 7.5 %
Table 1 Characteristics of the studied population
All No diabetes Type 1 diabetes Type 2 diabetes
Gender (Males:Females) 51 M:64 F 20 M:28 F 2 M:9 F 28 M:28 F
Age
(years; mean ± SD)
55.9 ± 15.3 46.2 ± 14.4 45.0 ± 12.8 64.8 ± 10.0
WB HbA1c
(%; mean ± SD)
6.22 ± 1.11 % 5.41 ± 0.35 % 7.80 ± 0.81 % 6.61 ± 1.11 %
Note: WB = whole blood; SD = standard deviation
Table 2 Summary of HbA1c results from WB, capillary DBS and
venous DBS samples
Day Sample HbA1c
(%, Mean ± SD)
Intra-assay CV %
(median, range)
D0 WB 6.22 ± 1.11 (N = 115) 1.19, 0–4.10
Uncorrected capDBS 6.62 ± 1.16 (N = 77) 2.28, 0–10.10
Corrected capDBS 6.39 ± 1.17 (N = 77) N/A
Uncorrected venDBS 6.72 ± 1.20 (N = 81) 1.68, 0–6.86
Corrected venDBS 6.42 ± 1.18 (N = 81) N/A
D4 Uncorrected capDBS 6.92 ± 1.32 (N = 96) 2.28, 0–9.87
Corrected capDBS 6.26 ± 1.18 (N = 96) N/A
Uncorrected venDBS 7.15 ± 1.39 (N = 81) 2.14, 0–11.79
Corrected venDBS 6.42 ± 1.21 (N = 81) N/A
D7 Uncorrected capDBS 6.85 ± 1.29 (N = 81) 1.98, 0–16.04
Corrected capDBS 6.25 ± 1.15 (N = 81) N/A
Uncorrected venDBS 7.36 ± 1.47 (N = 75) 2.81, 0–26.42
Corrected venDBS 6.51 ± 1.23 (N = 75) N/A
D14 Uncorrected capDBS 6.62 ± 1.44 (N = 79) 2.62, 0–17.68
Corrected capDBS 6.10 ± 1.33 (N = 79) N/A
Uncorrected venDBS 7.30 ± 1.65 (N = 79) 2.54, 0–26.52
Corrected venDBS 6.44 ± 1.29 (N = 79) N/A
Note: WB = whole blood; ven = venous; cap = capillary; DBS = dried blood spot;
SD = standard deviation; CV = coefficient of variation; N/A = not applicable
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tervals for all days. DBS values were applied to equations
derived from linear regression analyses from D0, D4, D7
and D14 data, in order to obtain corrected DBS values
(i.e., to bring uncorrected DBS values closer to the line
of equality). Bland-Altman plots were constructed with
corrected D0, D4, D7 and D14 results.
Results
A total of 115 participants (n = 51 males, n = 64 females)
were recruited. Mean age was 55.9 ± 15.3 years-old; 11
participants (9.6 %) had been previously diagnosed with
type 1 diabetes, and 56 individuals (48.7 %) had type 2
diabetes. Overall mean whole blood HbA1c levels were
6.22 ± 1.11 % (5.41 ± 0.35 % for participants without dia-
betes, 7.80 ± 0.81 % for volunteers with type 1 diabetes,
and 6.61 ± 1.11 % among individuals with type 2
diabetes). Characteristics of the studied participants are
summarised in Table 1.
Whole blood and dried blood spot samples (capillary
and venous) were measured in duplicates or triplicates,
allowing the determination of intra-assay CV. The median
intra-assay CVs were 1.19 % for WB (range 0–4.1 %), and
lower than 3 % for all other samples (Table 2).
Mean ± SD capillary DBS (capDBS) levels of HbA1c
were 6.62 ± 1.16 % when measured on D0 (n = 77), 6.92
± 1.32 % on D4 (n = 96), 6.85 ± 1.29 % on D7 (n = 81),
and 6.62 ± 1.44 % on D14 (n = 79). Venous DBS
(venDBS) samples ranged from 6.72 ± 1.20 % on D0 to
7.36 ± 1.47 % on D7. Mean capDBS and venDBS values
were applied to correction formulas obtained from linear
regression analyses for each day. Corrected DBS values
were closer to WB results (except for D14). Table 2
summarizes the results from WB and DBS samples (cor-
rected and uncorrected).
Bland-Altman plots of difference in HbA1c values in
WB and corrected capDBS (Fig. 1), and in WB and cor-
rected venDBS (Fig. 2) showed good correlation and
agreement between the two methods, with few samples
falling outside the 95 % limits of agreement for each
comparison (average difference ± 1.96 standard deviation
of the difference). However, limits of agreement were
broader on D14 (Table 3).
From any given capDBS result, the linear regression
models predicted WB values that were generally lowerthan the measured capDBS values. For example, for
capDBS HbA1c results of 4 %, the predicted WB values
were 3.84 % on Day 0, 3.86 % on Day 4, 3.97 % on Day
7, and 4.48 % on Day 14. For capDBS HbA1c results of
7 %, the predicted WB values were 6.76 % on Day 0,
6.33 % on Day 4, 6.37 % on Day 7, and 6.33 % on Day
14. For capDBS HbA1c results of 7.5 %, the predicted
WB values were 7.25 % on Day 0, 6.73 % on Day 4,
6.77 % on Day 7, and 6.64 % on Day 14. For capDBS
HbA1c results of 10 %, the predicted WB values were
9.69 % on Day 0, 8.79 % on Day 4, 8.78 % on Day 7, and
8.19 % on Day 14. The width of the 95 % prediction
intervals (a measure of how precisely WB can be
estimated) varied more broadly on D14. The estimated
mean squared error (MSE) was lower on Days 0 and 4
when using the linear regression model, which also
determined further decreases in R2 values on D7 and
D14 (Table 4).








































































































































Fig. 1 Bland-Altman plots of capillary dried blood spot samples from days 0, 4, 7 and 14. Note: Corrected DBS results are represented on D0, D4, D7
and D14; dashed lines represent 95 % limits of agreement; full lines represent biases. WB =whole blood on D0; cap = capillary; DBS = dried blood spot
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There is growing demand for human pathology test ser-
vices in Australia and around the world, driven by the
ageing global population and increasing incidence of
chronic diseases [13]. Dried blood spot sampling is an
alternative to traditional blood sampling, and has been
used in clinical and epidemiological studies for several
decades [6, 8, 14]. This method provides results that are
comparable to those obtained through traditional veni-
pucture [2, 12], without its logistical obstacles regarding
sample collection, processing, transportation and stor-
age. For the measurement of HbA1c, DBS has also been
shown to produce results that are comparable to those ob-
tained through venous sampling [15–25]. In our study, we
showed that HbA1c levels from DBS samples collected via
finger pricking from volunteers with and without diabetes
were comparable to those measured from venous samples,
when measured up to seven days after collection.
In our study, DBS samples collected from finger
pricking (capDBS) were analysed on the same day (D0),four (D4), seven (D7) and fourteen (D14) days after
collection. High correlation and agreement between
capDBS results on D0 and venous blood HbA1c values
showed that the analysis of samples collected on matrix
paper and analysed immediately provides results that
are similar to those obtained and processed by trad-
itional methods.
In a real-life scenario, DBS samples are mailed or
shipped to the pathology laboratory that performs the
assays. Therefore, DBS samples are not analysed immedi-
ately. To assess whether this gap between collection and
analysis may interfere with the results, we performed ana-
lyses also four, seven and fourteen days after collection.
We observed that, over time, the correlation between DBS
and venous blood results becomes weaker, and the 95 %
limits of agreement become wider, especially for D14
results, which may be clinically unacceptable. It is note-
worthy that WB samples also degrade over time when not
analysed immediately, particularly if not kept refrigerated.
Haemoglobin degradation products may show up in





























































































































Fig. 2 Bland-Altman plots of venous dried blood spot samples from days 0, 4, 7 and 14. Note: Corrected DBS results are represented on D0, D4, D7
and D14; dashed lines represent 95 % limits of agreement; full lines represent biases. WB =whole blood on D0; cap = capillary; DBS = dried blood spot
Table 3 95% limits of agreement for capillary and venous DBS
results, uncorrected and corrected
Upper limit Lower limit
Uncorrected Corrected Uncorrected Corrected
D0 Capillary 0.2308 0.462 −0.6828 −0.463
Venous 0.1174 0.404 −0.7051 −0.402
D4 Capillary 0.1117 0.638 −1.428 −0.636
Venous 0.1203 0.671 −1.567 −0.666
D7 Capillary 0.2383 0.668 −1.436 −0.668
Venous 0.2345 0.845 −1.943 −0.845
D14 Capillary 1.111 1.484 −2.151 −1.485
Venous 0.6642 1.065 −2.373 −1.069
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may co-elute with, or be incompletely separated from,
HbA1c. In these cases, the HbA1c value obtained may be
reported as higher than it actually is [26]. This effect is
particularly evident for venDBS samples, which were col-
lected without anticoagulant.
We used a linear regression model for cross-validation,
to ensure unbiased measures of goodness-of-fit and
prediction intervals for WB. In that model, capD0-DBS
results were closer to the predicted WB values for all
evaluated HbA1c steps (4 %, 7 %, 7.5 %, and 10 %), and
the prediction intervals were narrower. On the
remaining days, capDBS results were further away from
the predicted WB values, and the prediction intervals
broadened over time. In the clinics, capD0-DBS sam-
ples would provide the most accurate HbA1c results,
closer to the predicted WB results and with a narrower
prediction interval. However, the difference between
predicted WB and both capD4- and capD7-DBS results
Table 4 Prediction intervals for WB from capillary DBS values of 4 %, 7 %, 7.5 % and 10 %, obtained through linear regression
models

















D0 3.84 3.36 4.32 6.76 6.30 7.23 7.25 6.78 7.72 9.69 9.20 10.18 0.0554 0.9463
D4 3.86 3.22 4.51 6.33 5.70 6.95 6.74 6.11 7.36 8.79 8.14 9.43 0.0992 0.9064
D7 3.97 3.26 4.67 6.37 5.68 7.06 6.77 6.08 7.46 8.77 8.06 9.49 0.1247 0.8267
D14 4.48 3.20 5.76 6.33 5.08 7.59 6.64 5.38 7.90 8.19 6.89 9.48 0.3905 0.5268
Note: pWB = predicted whole blood; capDBS = capillary dried blood spot; MSE: mean standard error; CI: confidence interval
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intervals. In the case of capD14-DBS results, their pre-
diction intervals may be too wide to be clinically accept-
able. We applied four different capDBS values to the
model, but any result can be applied to it (R program
available upon request), providing similar behaviour.
In some cases, patients may have difficulty in collecting
sufficient amount of blood samples from finger pricking
on the matrix paper. That difficulty was evidenced by the
fact that the sample size for each day was not equal to the
total number of recruited participants. Therefore, we
assessed whether venous blood collected through standard
methods and spotted on the matrix paper would produce
similar results. In those analyses, venous DBS samples
were correlated to traditionally-processed venous blood
samples in a similar way as capillary DBS. Also, there was
high correlation and agreement between capDBS and
venDBS results.
In our study, we recruited 67 diabetic patients. Most
of them had type 2 diabetes, and had HbA1c levels that
are considered adequate (particularly among participants
with type 2 diabetes). Only three participants had
HbA1c levels higher than 9 %. Therefore, results might
have been different should more participants with de-
compensated diabetes had been recruited. Samples were
measured at least in duplicates, and the median intra-
assay coefficients of variation were clinically acceptable,
lower than 3 % at all times. However, some participants
had heterogeneous results. It is unclear why results
using the same sample and assay method may vary in
some participants.
One of the key issues to be considered for the
employment of DBS sampling is the standardization of
the analysis of the DBS measurements. It is essential to
predict, with the highest possible level of accuracy, the
concentration of HbA1c in WB from the values
measured in the DBS tests. In a recent study, a meta-
analysis of seventeen heterogeneous studies (employing
different methods for measuring HbA1c) was per-
formed by Affan et al., and a correction formula to
approximate the DBS results to the WB values waspublished (12). We employed their correction formula
in our current studies (results not presented), but the
outcomes of the corrected DBS values resulted in a
poorer approximation to the WB values. It appears that
the time elapsed between sample collection and pro-
cessing is a key component of the variability observed
in the DBS sampling. Indeed, we found that there are
significant differences among the Bland-Altman plots
constructed from data on each particular day (e.g. D0,
D4, D7 and D14) between DBS vs. WB. Thus, in our
current analytical method, we analysed the data of each
processed day independently by proposing mean values
and prediction intervals for each particular processing
day. Additionally, we corrected capillary DBS results by
applying a correction formula that derived from regres-
sion analyses for each particular day, to approximate
the regression line to the equality line. Thus, we obtained
a different formula for each day, and observed that cor-
rected capillary DBS results were closer to the predicted
WB ones on all days except D14, when MSE was higher
(i.e., WB results were less precisely predicted).
We acknowledge that our study is limited by the fact
that participants were evaluated in a controlled research
setting, and results may be different when capillary
HbA1c is evaluated in a real-life scenario. Future studies
need to evaluate samples from participants who collect
their capillary DBS samples on their own, and mail them
to the testing laboratory via standard postal services
(subjected to confounding factors such as delays and
temperature variations). Furthermore, future studies
should evaluate the prediction intervals for other elapsed
times such as D1, D2, and D3, and also determine how
these prediction intervals can be applied in the manage-
ment of diabetes. To answer those questions, future
studies should evaluate healthy individuals and those
with diabetes who are treatment-naïve, and compare
their DBS values and their prediction intervals with their
WB HbA1c outcomes. By considering their WB values
as the gold-standard, a more accurate clinical interpret-
ation of the prediction intervals, as proposed here, could
be established.
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In conclusion, HbA1c measured from DBS samples
collected via finger pricking provided results that were
comparable to those obtained from venous samples and
measured by standard procedures. When results from
DBS samples (processed up to 7 days after their collec-
tion) were applied to correction equations, HbA1c
results with the most accuracy and the least clinically-
acceptable variability were obtained, with high correlation
and agreement to HbA1c results from whole venous
blood, and with narrow 95 % limits of agreement. Those
findings were further confirmed by a cross-validation
model, which provided prediction intervals that were
narrow enough to be clinically acceptable. In order for the
measurement of HbA1c through DBS sampling to be
considered in situations where traditional venipuncture is
not available, further studies need to evaluate the effects of
external factors, in a broader population.
Competing interests
This study was funded by MyHealthTest Pty. MyHealthTest Pty funded the
article-processing charge; MyHealthTest Pty staff instructed participants how
to collect their capillary blood samples. MyHealthTest Pty had no role in study
design, data analysis and interpretation of data, writing of the manuscript, and
decision to submit the manuscript for publication. All authors had and have full
access to the study data.
Authors’ contributions
BW performed samples collection, developed the DBS elution protocol,
performed samples assays, performed data analysis, wrote the manuscript;
CAM designed the study, performed data analysis, wrote the manuscript. RT
performed samples collection, developed the DBS elution protocol, performed
samples assays. TN designed the study, performed data analysis, wrote the
manuscript. GP-F designed the study, performed samples collection, performed
data analysis, wrote the manuscript. All authors read and approved the final
manuscript.
Authors’ information
Claudio A. Mastronardi and Belinda Whittle considered co-first authors.
Acknowledgements
We thank MyHealthTest Pty staff, Dr. Marianne Gould (for logistical
assistance), and Ms. Jennifer Orr (for her assistance with capillary blood
samples collection). We also thank DiabetesACT for their assistance with
the recruitment of volunteers. This study was funded by MyHealthTest Pty,
including the article-processing charge.
Author details
1Department of Genome Sciences, The John Curtin School of Medical
Research, The Australian National University, 131 Garran Rd, Canberra, Acton
ACT 2601, Australia. 2Australian Phenomics Facility, The Australian National
University, 117 Garran Rd, Canberra, Acton ACT 2601, Australia. 3Statistical
Consulting Unit, The Australian National University, 27 Union Lane, Canberra,
Acton ACT 2601, Australia.
Received: 25 March 2015 Accepted: 24 June 2015
References
1. American Diabetes A. Standards of medical care in diabetes–2014. Diabetes
Care. 2014;37 Suppl 1:S14–80.
2. McDade TW. Development and validation of assay protocols for use with
dried blood spot samples. Am J Hum Biol. 2014;26(1):1–9.
3. Bang I. Ein verfahren zur mikrobestimmung von blutbestandteilen. Biochem
Ztschr. 1913;49:19–39.4. Guthrie R, Susi A. A Simple Phenylalanine Method for Detecting
Phenylketonuria in Large Populations of Newborn Infants. Pediatrics.
1963;32:338–43.
5. Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the
collection and analysis of human whole blood specimens. J Nutr.
2001;131(5):1631S–6.
6. Parker SP, Cubitt WD. The use of the dried blood spot sample in
epidemiological studies. J Clin Pathol. 1999;52(9):633–9.
7. Bhatti P, Kampa D, Alexander BH, McClure C, Ringer D, Doody MM, et al.
Blood spots as an alternative to whole blood collection and the effect of a
small monetary incentive to increase participation in genetic association
studies. BMC Med Res Methodol. 2009;9:76.
8. Wilcken B, Wiley V. Newborn screening. Pathology. 2008;40(2):104–15.
9. Corran PH, Cook J, Lynch C, Leendertse H, Manjurano A, Griffin J, et al. Dried
blood spots as a source of anti-malarial antibodies for epidemiological studies.
Malar J. 2008;7:195.
10. Sherman GG, Stevens G, Jones SA, Horsfield P, Stevens WS. Dried blood
spots improve access to HIV diagnosis and care for infants in low-resource
settings. J Acquir Immune Defic Syndr. 2005;38(5):615–7.
11. Xu YY, Pettersson K, Blomberg K, Hemmila I, Mikola H, Lovgren T. Simultaneous
quadruple-label fluorometric immunoassay of thyroid-stimulating hormone, 17
alpha-hydroxyprogesterone, immunoreactive trypsin, and creatine kinase MM
isoenzyme in dried blood spots. Clin Chem. 1992;38(10):2038–43.
12. Affan ET, Praveen D, Chow CK, Neal BC. Comparability of HbA1c and lipids
measured with dried blood spot versus venous samples: a systematic
review and meta-analysis. BMC Clin Pathol. 2014;14:21.
13. Britt H. An analysis of pathology test use in Australia. Australian Association
of Pathology Practices Inc. 2008. Available from http://pathologyaustralia.
com.au/wp-content/uploads/2013/03/DOD-paper-+-append.pdf.
Accessed 7 May 2015.
14. Williams SR, McDade TW. The use of dried blood spot sampling in the
national social life, health, and aging project. J Gerontol B Psychol Sci Soc
Sci. 2009;64 Suppl 1:i131–6.
15. Anjali, Geethanjali FS, Kumar RS, Seshadri MS. Accuracy of filter paper
method for measuring glycated hemoglobin. J Assoc Physicians India.
2007;55:115–9.
16. Egier DA, Keys JL, Hall SK, McQueen MJ. Measurement of hemoglobin A1c
from filter papers for population-based studies. Clin Chem. 2011;57(4):577–85.
17. Fokkema MR, Bakker AJ, de Boer F, Kooistra J, de Vries S, Wolthuis A. HbA1c
measurements from dried blood spots: validation and patient satisfaction.
Clin Chem Lab Med. 2009;47(10):1259–64.
18. Gay EC, Cruickshanks KJ, Chase HP, Klingensmith G, Hamman RF. Accuracy
of a filter paper method for measuring glycosylated hemoglobin. Diabetes
Care. 1992;15(1):108–10.
19. Jeppsson JO, Jerntorp P, Almer LO, Persson R, Ekberg G, Sundkvist G.
Capillary blood on filter paper for determination of HbA1c by ion exchange
chromatography. Diabetes Care. 1996;19(2):142–5.
20. Jones TG, Warber KD, Roberts BD. Analysis of hemoglobin A1c from dried
blood spot samples with the Tina-quantR II immunoturbidimetric method.
J Diabetes Sci Technol. 2010;4(2):244–9.
21. Lacher DA, Berman LE, Chen TC, Porter KS. Comparison of dried blood spot
to venous methods for hemoglobin A1c, glucose, total cholesterol,
high-density lipoprotein cholesterol, and C-reactive protein. Clin Chim
Acta. 2013;422:54–8.
22. Lakshmy R, Gupta R. Measurement of glycated hemoglobin A1c from dried
blood by turbidimetric immunoassay. J Diabetes Sci Technol.
2009;3(5):1203–6.
23. Little RR, McKenzie EM, Wiedmeyer HM, England JD, Goldstein DE.
Collection of blood on filter paper for measurement of glycated
hemoglobin by affinity chromatography. Clin Chem. 1986;32(5):869–71.
24. Lomeo A, Bolner A, Scattolo N, Guzzo P, Amadori F, Sartori S, et al. HPLC
analysis of HbA1c in dried blood spot samples (DBS): a reliable future for
diabetes monitoring. Clin Lab. 2008;54(5–6):161–7.
25. Wikblad K, Smide B, Bergstrom A, Wahren L, Mugusi F, Jeppsson JO.
Immediate assessment of HbA1c under field conditions in Tanzania.
Diabetes Res Clin Pract. 1998;40(2):123–8.
26. Selvin E, Coresh J, Jordahl J, Boland L, Steffes MW. Stability of haemoglobin
A1c (HbA1c) measurements from frozen whole blood samples stored for
over a decade. Diabet Med. 2005;22(12):1726–30.
